Turku, Finland

Päivi Vuorio


 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2011-2012

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Päivi Vuorio: Innovator in Anti-VAP-1 Antibodies

Introduction

Päivi Vuorio is a notable inventor based in Turku, Finland. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies. With a total of 2 patents, his work focuses on innovative methods for treating inflammatory conditions.

Latest Patents

Vuorio's latest patents include groundbreaking methods of treating inflammatory conditions involving VAP-1-mediated adhesion with VAP-1-specific antibodies. These patents disclose novel fully human anti-VAP-1 antibodies and fragments thereof. Additionally, they cover nucleic acids encoding these antibodies, as well as expression vectors and host cells that facilitate the recombinant expression of anti-VAP-1 antibodies. Pharmaceutical compositions comprising these antibodies and their therapeutic uses are also detailed in his patents. Another significant patent involves fully human anti-VAP-1 monoclonal antibodies, further emphasizing his expertise in this area.

Career Highlights

Päivi Vuorio is associated with Biotie Therapies Corporation, where he continues to advance his research and development efforts. His work has been instrumental in creating innovative solutions for medical challenges related to inflammatory conditions.

Collaborations

Vuorio collaborates with esteemed colleagues, including David Smith and Petri Vainio, to enhance the impact of his research and innovations.

Conclusion

Päivi Vuorio's contributions to the field of biotechnology, particularly through his patents on anti-VAP-1 antibodies, highlight his role as a leading inventor in the industry. His work promises to advance therapeutic options for patients suffering from inflammatory conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…